Hosted on MSN19d
Gilead Sciences CFO sells shares worth $228,375
Andrew D. Dickinson, the Chief Financial Officer of Gilead Sciences, Inc. (NASDAQ:GILD), a prominent biotechnology company with a market capitalization of $113 billion and "GREAT" financial health ...
BioSpace1d
Trump’s Tariffs Threaten Big Pharma With Higher Costs and Slimmer Margins
J&J, AstraZeneca, Novo Nordisk and Roche are among the companies that might take a hit from the soon-to-be-enacted fees, ...
BioSpace13d
Almost 5 Years into $5B Galapagos Partnership, Gilead Execs Start Over With New Spinoff
Gilead signed a massive deal with Galapagos. After a restructuring, the pharma is still hunting for the potential it saw at ...
MedCity News20d
Galapagos CEO Tells JPM Audience the Rationale for Planned Business Separation
In a separate Gilead briefing with journalists on Wednesday, Gilead Chief Financial Officer Andy Dickinson said Galapagos and Gilead came to the realization that Galapagos management was spending ...
bovnews1d
What’s Fueling Gilead Sciences Inc (GILD) Stock’s 21.99% Gain Above Its 200-Day SMA?
Gilead Sciences Inc (GILD) stock saw a modest uptick, ending the day at $97.2 which represents a slight increase of $0.25 or 0.26% from the prior close of $96.95. The stock opened at $96.73 and ...